Extraction form for project: Screening for Glaucoma in Adults - 1 of 2

Design Details

1. Study design

Arms

Arm NameArm Description
A. Drug treatment targeting IOP of 24 mm Hg or less or a 20% reduction in IOP (n=817)
B. No treatment (n=819)

Sample Characteristics

1. N
A. Drug treatment targeting IOP of 24 mm Hg or less or a 20% reduction in IOP (n=817)
B. No treatment (n=819)
Total
2. Baseline population
A. Drug treatment targeting IOP of 24 mm Hg or less or a 20% reduction in IOP (n=817)
B. No treatment (n=819)
Total

Outcomes

TypeDomainSpecific measurement (i.e., tool/definition/specific outcome)PopulationsTimepoints
CategoricalVision disorderIOP, reduction from baseline
  • All Participants
  • end of study
CategoricalVision disorderProgression of visual field defects or optic disc changes for any reason
  • All Participants
  • end of study

Risk of Bias Assessment

1. Random assignment
2. Allocation concealed
3. Groups similar at baseline
4. Eligibility criteria specified
5. Blinding: outcome assessors or data analysts
6. Intention-to-treat analysis
7. Reporting of attrition, contamination, etc.
8. Differential loss to followup or overall high loss to followup
9. Appropriate analysis including cluster correlation
10. Funding source
11. Randomization adequate?
12. Allocation concealment adequate?
13. Groups similar at baseline?
14. Eligibility criteria specified?
15. Outcome assessors masked?
16. Care provider masked?
17. Patient masked?
18. Attrition and withdrawals reported?
19. Loss to followup differential/ high?
20. People analyzed in the groups in which they were randomized?
21. Quality

Results

Categorical


Vision disorder (IOP, reduction from baseline)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Drug treatment targeting IOP of 24 mm Hg or less or a 20% reduction in IOP (n=817)B. No treatment (n=819)
end of study
IOP reduction
Odds Ratio (OR)
95% CI low (OR)
95% CI high (OR)
Risk Ratio (RR)
95% CI low (RR)
95% CI high (RR)
p value
Within Arm ComparisonsNet Comparisons
A. Drug treatment targeting IOP of 24 mm Hg or less or a 20% reduction in IOP (n=817)B. No treatment (n=819)

Vision disorder (Progression of visual field defects or optic disc changes for any reason)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Drug treatment targeting IOP of 24 mm Hg or less or a 20% reduction in IOP (n=817)B. No treatment (n=819)
All Arms (ANOVA)
end of study
IOP reduction
Risk Ratio (RR)
Total (N analyzed)
95% CI low (RR)
Events
95% CI high (RR)
Percentage
Within Arm ComparisonsNet Comparisons
A. Drug treatment targeting IOP of 24 mm Hg or less or a 20% reduction in IOP (n=817)B. No treatment (n=819)
All Arms (ANOVA)